Hartauer, et al., “A comparison of diffuse reflectance FT-IR spectroscopy and DSC in the characterization of a drug-excipient interaction”, Drug Development and Industrial Pharmacy, 1991, 17(4):617-630. |
Blaug, et al., “Interaction of dextroamphetamine sulfate with stpay-dried lactose”, J. of Pharm. Sciences, 1972, 61(11):1770-1775. |
Castello, et al., “Discoloration of tablets containing amines and lactose”, J. of Pharm. Sciences, 1962, 51(2):106-108. |
Wade, et al., Handbook of Pharmaceutical Excipients (2nd edition), American Pharma. Assoc. & the Pharma. Press, Royal Pharma. Society of G. Britain, pp. 257-259 (1994). |
Wirth, et al., “Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine”, J. of Pharm. Sciences, 1998, 87(1):31-39. |
Babe, et al., The Pharmacological Basis of Therapeutics (9th edition), The McGraw-Hill Co. Inc., pp. 581-599 (1996). |
Andersen, et al., “Adverse drug interactions clinically important for the dermatologist”, Arch Dermatol, 1995, 131:468-473. |
Barnett, et al., New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991). |
Berge, et al., “Pharmaceutical slats”, J. of Pharm. Sciences, 1977, 66(1):1-19.. |
Berthon, et al., “In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)”, Biochem. Pharm., 1994 47(5):789-794. |
Brandes, et al., “Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates”, J. of the National Cancer Inst., 1994, 86(10):770-775. |
Brandes, et al., “Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses”, Cancer Research, 1992, 52:3796-3800. |
Brion, et al., “Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers”, Br. J. clin. Pharmac. 1988, 25:27-32. |
Carmeliet, “Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide”, The J. of Pharm. And Experimental Therapeutics, 1992, 262(2):809-817. |
Cheung, et al., “Investigation of anti-motion sickness drugs in the squirrel monkey”, J. Clin. Pharmacol, 1992, 32:163-175. |
Clissold, et al., “Loratadine a preliminary review of its pharmacodynamic properties and therapeutic efficacy”, Drugs, 1989, 37:42-57. |
Cooke, “Glycopyrrolate in bladder dysfunction”, SA Medical Journal, 1983, 3. |
Craft, “Torsade de pointes after astemizole overdose”, Br. Medical Journal, 1986, 292:660. |
Dorje, et al., “Antagonist binding profiles of five cloned human muscarinic receptor subtypes”, The J. of Pharm. And Experimental Therapeutics, 1991, 256:727-733. |
Lunde, Side Effects of Drugs Annual 12; A worldwide yearly survey of new data and trends, Elsevier Science Publishers B.V., 1988, 142-143. |
Ebert, “Soft elastic gelatin capsules: a unique dosage form”, Pharmaceutical Technology, 1977, 44-50. |
Gengo, “Dilemma: Antihistamine selection: Use vs. Side effects”, U.S. Pharmacist, Nov. 1990, 59-92. |
Regula Herzog, et al., Annual Review of Gerontology and Geriatrics, 1989, 9:74-119. |
Hilbert, et al., “Pharmacokinetics and dose proportionality of loratadine”, J. Clin. Pharmacol. 1987, 27:694-698. |
Housley, et al., “Histamine and related substances influence neurotransmission in the semicircular canal”, Hearing Research, 1988, 35:87-98. |
Jankowski, et al., “Effect of terfenadine on nasal provocation”, Int. Arch. Allergy Immunol., 1993, 101:311-317. |
Kaliner, “Nonsedating antihistamines: Pharmacology, clinical efficacy and adverse effects”, American Family Physician, Mar. 1992, 45(3):1337-1342. |
Kleine-Tebbe, et al., “Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine”, J. Allergy Clin. Immunol., 1994, 93:494-500. |
Knowles, “Astemizole and terfenadine-induced cardiovascular effects”, The Canadian J. of Hospital Pharmacy, Feb. 1992, 45(1):33-37. |
Kohl, et al., “Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man”, Aviation, Space, and Environmental Medicine, Dec. 1987, 1171-1174. |
Kohl, et al., “New pharmacologic approaches to the prevention of space/motion sickness”, J. Clin. Pharmacol., 1991, 31:934-946. |
Kohl, et al., “Control of nausea and autonomic dysfunction with terfenadine, a peripherally acting antihistamine”, Aviation, Space, and Environmental Medicine, May 1991, 392-396. |
Kubo, et al., “Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor-binding assay”, Japan J. Pharmacol., 1987, 43:277-282. |
Lathers, et al., “Pharmacology in space: Part 2. Contolling motion sickness”, TiPS, Jun. 1989, 10:243-250. |
Levin, et al., “Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder”, The J. of Urology, Aug. 1982, 128:396-398. |
Lunde, Side Effects of Drugs Annual 14, Elsevier Science Publishers B.V., 1990, 135-143. |
Massad, et al., “The pharmacokinetics of intravesical and oral oxybutynin chloride”, The J. of Urology, Aug. 1992, 148:595-597. |
Miadonna, et al., “Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils”, Int. Arch Allergy Immunol., 1994, 105:12-17. |
Mirakhur, et al., “Glycopyrrolate: pharmacology and clinical use”, Anaesthesia, 1983, 38:1195-1204. |
Mitchelson, “Pharmacological agents affecting emesis: A review (Part II)”, Drugs, 1992, 43(4):443-463. |
Muskat, et al., “The use of scopolamine in the treatment of detrusor instability”, The J. of Urology, 1996, 156:1989-1990. |
Nelemans, Side Effects of Drugs Annual 12, Elsevier Science Publishers B.V., 1988, 144-147. |
Parkinson, et al., “Evaluation of Loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice”, Biochemical Pharmacology, 1992, 43(10):2169-2180. |
Peggs, et al., “Antihistamines; The old and the new”, American Family Physician, Aug. 1995,52(2):593-600. |
Petrin, “Bewegungskrankheit und ihre therapie/Eine Ubersicht (Motion sickness and its treatment)”, Schweiz, Rundschau Med., 1974, (PRAXIS) 63:79-81. |
Quercia, et al., “Focus on Laratadine: A new second-generation nonsedating H1-receptor antagonist”, Hosp. Formul., 1993, 28:137-153. |
Resnick, “Urinary incontinence”, The Lancet, 1995, 346:94-99. |
Roman, et al., “Loratadine-A review of recent finding in pharmacology pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine”, Clin. Reviews in Allergy, 1993, 11:89-110. |
Simons, “H1-receptor antagonist Comparative tolerability and safety”, Drug Safety, 1994, 10(5):350-380. |
Temple, et al., “Loratadine, an antihistamine, blocks antigen-and ionophore-induced leukotriene release from human lung in vitro”, Prostaglandins, Apr. 1988, 35(4):549-554. |
Sunahara, et al., “Pharmacological interventions for motion sickness: Cardiovascular Effects”, Aviation, Space and Environmental Medicine, Sep. 1987, A270-A276. |
Zhong, et al., “HPLC-Determination of Loratadine and its active metabolite descarboethoxyloratadine in human plasma”, Pharmazie, 1994, 49(H. 10):736-739. |
Yarker, et al., “Oxybutynin,. A review of its pharmacodynamic and phamocikinetic properties, and its therapeutic use in detrusor instability”, Drugs and Aging, 1995, 6(3):243-262. |
Wood, et al., “Mechanisms of antimotion sickness drugs”, Aviation, Space, and Environmental Medicine, Sep. 1987, A262-A265. |
Wood, “Antimotion sickness and antiemetic drugs”, Drugs, 1979, 17:471-479. |
Wein, “Pharmacology of incontinence”, Urologic Clinics of North America, Aug. 1995, 22(3):557-577. |
Van Cauwenberge, “New data on the safety of Loratadine”, Drug Invest., 1992, 4(4):283-291. |
McCue, “Safety of antihistamines in the treatment of allergic rhinitis in elderly patients”, Arch. Fam. Med., 1996, 5:464-468. |